CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2014 - 2026)

CytomX Therapeutics has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $979000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 93.96% year-over-year to $979000.0; the trailing twelve-month figure through Mar 2026 stood at $979000.0 (down 93.96% YoY), and the FY2025 full-year result was $1.6 million, down 94.08% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $979000.0, down from $1.6 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $222.1 million in Q1 2022, with the low at $979000.0 in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $85.7 million across 5 years, with a median of $59.7 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue dropped 17.06% — and 2025, when it tumbled 94.08%.
• CytomX Therapeutics' Non-Current Deffered Revenue stood at $180.1 million in 2022, then sank by 55.54% to $80.0 million in 2023, then sank by 66.44% to $26.9 million in 2024, then plunged by 94.08% to $1.6 million in 2025, then tumbled by 38.43% to $979000.0 in 2026.
• The last three Non-Current Deffered Revenue figures came in at $979000.0 (Q1 2026), $1.6 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.